Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Details

Serval ID
serval:BIB_2E56945E5E7C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.
Journal
Oncoimmunology
Author(s)
Hasan Ali O., Diem S., Markert E., Jochum W., Kerl K., French L.E., Speiser D.E., Früh M., Flatz L.
ISSN
2162-4011 (Print)
ISSN-L
2162-4011
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
5
Number
11
Pages
e1231292
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) in 40 patients with metastatic NSCLC treated with the anti-PD-1 antibody nivolumab. 7 out of 40 patients (17%) developed an irAEs. Skin irAEs correlated with tumor responses in 5 of 12 responders (42%) as compared to 2 of 27 non-responders (7%). Histologically, scaly plaques showed dermatitis consisting mainly of lymphocytes. We observed a positive correlation between skin irAEs and tumor responses in patients with NSCLC treated with nivolumab. Patterns of lymphocytic skin infiltration differed depending on the histological tumor subtype (adenocarcinoma versus squamous cell carcinoma NSCLC).

Pubmed
Open Access
Yes
Create date
29/12/2016 8:32
Last modification date
20/08/2019 13:12
Usage data